Search research articles
Contact Us
Filters
Showing results (71-80 of 187) with videos related to
Page
of 19
Sort By:
International Journal of Molecular Sciences
|
May 15, 2020
Disease-Specific Derangement of Circulating Endocannabinoids and <i>N</i>-Acylethanolamines in Myeloproliferative Neoplasms
Dorian Forte, Flaminia Fanelli, Marco Mezzullo, et al.
Haematologica
|
November 20, 2025
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review
Pankit Vachhani, Ruben Mesa, John Mascarenhas, et al.
Haematologica
|
November 13, 2012
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years
Nicola Vianelli, Francesca Palandri, Nicola Polverelli, et al.
Therapeutic Advances in Hematology
|
October 14, 2021
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
Monica Carpenedo, Erminia Baldacci, Claudia Baratè, et al.
Frontiers in Oncology
|
December 13, 2021
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
Monica Barone, Martina Barone, Francesca Ricci, et al.
Hematological Oncology
|
July 31, 2019
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach
Alessandra Iurlo, Elena Maria Elli, Francesca Palandri, et al.
The Lancet. Haematology
|
August 27, 2021
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
Alberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, et al.
Leukemia & Lymphoma
|
September 15, 2021
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
Paola Guglielmelli, Francesca Palandri, Carmine Selleri, et al.
JCO Precision Oncology
|
March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib
Andrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Haematologica
|
March 5, 2026
GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study
Richard F Schlenk, Claire N Harrison, Francesca Palandri, et al.
Page
of 19
Search research articles
Search
Showing results (71-80 of 187) with videos related to
Sort By:
Page
of 19
International Journal of Molecular Sciences
|
May 15, 2020
Disease-Specific Derangement of Circulating Endocannabinoids and <i>N</i>-Acylethanolamines in Myeloproliferative Neoplasms
Dorian Forte, Flaminia Fanelli, Marco Mezzullo, et al.
Haematologica
|
November 20, 2025
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review
Pankit Vachhani, Ruben Mesa, John Mascarenhas, et al.
Haematologica
|
November 13, 2012
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years
Nicola Vianelli, Francesca Palandri, Nicola Polverelli, et al.
Therapeutic Advances in Hematology
|
October 14, 2021
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
Monica Carpenedo, Erminia Baldacci, Claudia Baratè, et al.
Frontiers in Oncology
|
December 13, 2021
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
Monica Barone, Martina Barone, Francesca Ricci, et al.
Hematological Oncology
|
July 31, 2019
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach
Alessandra Iurlo, Elena Maria Elli, Francesca Palandri, et al.
The Lancet. Haematology
|
August 27, 2021
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
Alberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, et al.
Leukemia & Lymphoma
|
September 15, 2021
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
Paola Guglielmelli, Francesca Palandri, Carmine Selleri, et al.
JCO Precision Oncology
|
March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib
Andrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Haematologica
|
March 5, 2026
GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study
Richard F Schlenk, Claire N Harrison, Francesca Palandri, et al.
Page
of 19